McKesson Corporation (FRA:MCK)
610.00
-6.80 (-1.10%)
Last updated: Jul 18, 2025
Revenue by Product
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2020 |
Other | 11.00M | Log In | Log In | Log In | Log In | Upgrade |
Medical Surgical Solutions | 11.39B | Log In | Log In | Log In | Log In | Upgrade |
Medical Surgical Solutions Growth | 0.65% | Log In | Log In | Log In | Log In | Upgrade |
US Pharmaceutical | 327.72B | Log In | Log In | Log In | Log In | Upgrade |
US Pharmaceutical Growth | 17.57% | Log In | Log In | Log In | Log In | Upgrade |
Prescription Technology Solutions | 5.22B | Log In | Log In | Log In | Log In | Upgrade |
Prescription Technology Solutions Growth | 9.37% | Log In | Log In | Log In | Log In | Upgrade |
International | 14.72B | Log In | Log In | Log In | Log In | Upgrade |
International Growth | 4.18% | Log In | Log In | Log In | Log In | Upgrade |
Other | 11.00M | Log In | Log In | Log In | Log In | Upgrade |
Other | 11.00M | Log In | Log In | Log In | Log In | Upgrade |
Capex by Product
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2020 |
Other | 15.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Medical Surgical Solutions Capital Expenditures | 163.00M | Log In | Log In | Log In | Log In | Upgrade |
Medical Surgical Solutions Capital Expenditures Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | 15.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
US Pharmaceutical Capital Expenditures | 241.00M | Log In | Log In | Log In | Log In | Upgrade |
US Pharmaceutical Capital Expenditures Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Prescription Technology Solutions Capital Expenditures | 11.00M | Log In | Log In | Log In | Log In | Upgrade |
Prescription Technology Solutions Capital Expenditures Growth | - | Log In | Log In | Log In | Log In | Upgrade |
International Capital Expenditures | 107.00M | Log In | Log In | Log In | Log In | Upgrade |
International Capital Expenditures Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | 15.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
EBIT by Product
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2020 |
Other | -522.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 268.44% | Log In | Log In | Log In | Log In | Upgrade |
Other | -522.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 268.44% | Log In | Log In | Log In | Log In | Upgrade |
Medical Surgical Solutions Operating Profit | 773.00M | Log In | Log In | Log In | Log In | Upgrade |
Medical Surgical Solutions Operating Profit Growth | -18.80% | Log In | Log In | Log In | Log In | Upgrade |
Other | -522.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 268.44% | Log In | Log In | Log In | Log In | Upgrade |
US Pharmaceutical Operating Profit | 4.00B | Log In | Log In | Log In | Log In | Upgrade |
US Pharmaceutical Operating Profit Growth | 43.65% | Log In | Log In | Log In | Log In | Upgrade |
Prescription Technology Solutions Operating Profit | 875.00M | Log In | Log In | Log In | Log In | Upgrade |
Prescription Technology Solutions Operating Profit Growth | 4.79% | Log In | Log In | Log In | Log In | Upgrade |
International Operating Profit | -213.00M | Log In | Log In | Log In | Log In | Upgrade |
International Operating Profit Growth | -166.77% | Log In | Log In | Log In | Log In | Upgrade |